SecBot SecBot
8-K ·Filed Aug 31, 2026

BBIO

BridgeBio Pharma, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed2mo ago SEC0001140361-26-035055
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

Monitor for subsequent pricing detail disclosures or government program expansions that could affect Attruby's revenue trajectory. Key catalysts to watch are the upcoming PDUFA dates for BBP-418 (Nov 2026) and encaleret (May 2027).

DirectionNeutral
Confidencemedium
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20
Entry
$76.59
T+0 close · Aug 31, 2026 · via day close
Latest settled
−13.87%
T+20 · $65.97 · next T+60 in 7d
Vs SPY
−13.68%
α at T+20
Latest observation
+9.30%
T+52 · FF3 residual α
  1. T+0 · Aug 31 $76.59entry
  2. T+1 · 3mo ago −0.03%α +0.66% · $76.57
  3. T+5 · 2mo ago −2.39%α −2.25% · $74.76
  4. T+20 · 7w ago −13.87%α −13.68% · $65.97
  5. T+54 · todayOpen
  6. T+60 · in 7d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BridgeBio announced a voluntary agreement with the U.S. government to lower drug costs and expand Medicaid access to its marketed medicine Attruby, with no future pricing mandates expected. The specific terms are confidential, but the deal excludes medicines approved exclusively for orphan indications and has no impact on the company's existing copay assistance program.

Key Facts

  • Voluntary agreement with U.S. government to lower drug costs and expand Medicaid access to Attruby via the GENEROUS Model
  • BridgeBio expects no future pricing mandates under this agreement
  • Pricing commitments exclude medicines approved exclusively for orphan indications
  • Attruby will continue to be offered via Medicare Part D without future pricing mandates
  • The ForgingBridges copay assistance program is unaffected
  • Specific terms of the agreement remain confidential
  • CEO Neil Kumar joined President Trump at the White House to discuss the agreement
  • BridgeBio has three additional medicines under FDA review: BBP-418 (PDUFA Nov 27, 2026), encaleret (PDUFA May 7, 2027), and infigratinib for achondroplasia

Financial Impact

No specific dollar amounts disclosed, agreement terms are confidential. Impact on pricing and revenue for Attruby and future medicines is unquantifiable from this filing.

revenuepricingmedicaid accesspatient out-of-pocket costs

Risk Factors

  • Implementation of the agreement may differ from current expectations
  • Future changes in federal laws or pricing programs could override the agreement's protections
  • Confidential terms may have undisclosed revenue or pricing constraints

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (28 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001140361-26-035055
Document: ef20081330_ex99-1.htm0001140361-26-035055
Document: 0001140361-26-035055-index-headers.html0001140361-26-035055
Document: 0001140361-26-035055-index.html0001140361-26-035055
Document: 0001140361-26-035055.txt0001140361-26-035055

Track record

38 reports on BBIO

Performance horizon

10 of 13 bullish or bearish reports moved the stock their way by T+20. Best: +26.76% at T+60 after the May 11, 2026 report. 14 of 15 went positive at some point.

Filters
  1. Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $78.17 Now $78.30 +0.17% settles Dec 11
  2. Nov 9, 20267d ago Institutional Cluster Bullish 4/10 Entry $77.93 Now $78.30 +0.47% settles Dec 8
  3. Nov 6, 202610d ago Press Release Neutral 2/10 Entry $77.93 Now $78.30 +0.47% settles Dec 8
  4. Oct 29, 202618d ago 8-K Bullish 6/10 No price data
  5. Oct 29, 202618d ago Press Release Bullish 6/10 Entry $74.95 Now $78.30 +4.47% settles Nov 30
  6. Oct 27, 202620d ago SC 13G Neutral 3/10 Entry $70.82 Now $78.30 +10.56% settles Nov 25
  7. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $68.12 Now $78.30 +14.94% settles Nov 19
  8. Oct 13, 20264w ago 8-K Bullish 7/10 Entry $63.30 to $78.67 Now $78.30 +23.70% ▲ +24.28% +27.89% vs SPY
  9. Oct 6, 20265w ago Press Release Bullish 7/10 Entry $66.96 to $74.03 Now $78.30 +16.94% ▲ +10.56% +13.73% vs SPY
  10. Oct 5, 20266w ago Press Release Neutral 2/10 Entry $66.96 to $74.03 Now $78.30 +16.94% ▲ +10.56% +13.73% vs SPY
Showing 10 of 38

US Market Status

Market Closed · Opens Wed (13h 26m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 31, 2026